Hormonal therapies and gynaecological cancers.

Hormonal therapy has an established place in the management of women with gynaecological malignancies, including first-line therapy for recurrent receptor-positive endometrial cancer and low-grade stromal sarcoma. There is no place for adjuvant hormonal treatment of these cancers after primary surgery. Primary treatment with either oral or intra-uterine progestagens to preserve fertility in younger women with endometrial carcinoma is effective in about 70% of cases. Response rates to tamoxifen in advanced/recurrent ovarian cancers approximates 10%. To the authors' knowledge, no studies that reasonably compare different progestagens, different routes of therapy, different doses and different hormonal preparations have been published.
AuthorsAndrea Garrett, Michael A Quinn
JournalBest practice & research. Clinical obstetrics & gynaecology (Best Pract Res Clin Obstet Gynaecol) Vol. 22 Issue 2 Pg. 407-21 (Apr 2008) ISSN: 1521-6934 [Print] England
PMID17884734 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Progestins
  • Tamoxifen
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Aromatase Inhibitors (therapeutic use)
  • Endometrial Neoplasms (drug therapy)
  • Estrogen Replacement Therapy
  • Female
  • Genital Neoplasms, Female (drug therapy)
  • Humans
  • Ovarian Neoplasms (drug therapy)
  • Progestins (therapeutic use)
  • Sarcoma, Endometrial Stromal (drug therapy)
  • Tamoxifen (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: